p53 and bcl-2 immunohistochemical alterations in prostate cancer treated with radiation therapy

Urology

Volumn 51, Issue 2, 1998, Pages 346-351

  Huang, Andrew ^a   Gandour Edwards, Regina ^a   Rosenthal, Seth A ^a   Siders, Douglas B ^a   Deitch, Arline D ^a   Devere White, Ralph W ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

DNA; PROTEIN BCL 2; PROTEIN P53;

ARTICLE; CANCER RADIOTHERAPY; CELL SURVIVAL; CONTROLLED STUDY; DNA DAMAGE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RADIOSENSITIVITY; TREATMENT FAILURE;

HUMANS; IMMUNOHISTOCHEMISTRY; MALE; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; TREATMENT FAILURE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032006232     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(97)00636-5     Document Type: Article

References (22)

1. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1997. CA Cancer J Clin. 47:1997;5-27.
2. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science. 253:1991;49-53.
3. Kuerbitz SJ, Plunkett BS, Walsh WV, Kastan MB. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA. 89:1992;7491-7495.
4. Korsmeyer SJ. bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood. 80:1992;879-886.
5. Siders DB, Lee F. Histologic changes of irradiated prostatic carcinoma diagnosed by transrectal ultrasound. Hum Pathol. 23:1992;344-351.
6. deVere White RW, Deitch AD, Meyer-Haass GM, Siders DB, Lee F. Deoxyribonucleic acid ploidy in the irradiated prostate. World J Urol. 10:1992;173-178.
7. Wertz IE, Deitch AD, Gumerlock PH, Gandour-Edwards R, Chi SG, deVere White RW. Correlation of genetic and immunodetection of TP53 mutations in malignant and benign prostate tissue. Hum Pathol. 27:1996;573-580.
8. Finlay CA, Hinds PW, Tan TH, Elijahu D, Oren EM, Levine AJ. Activating mutations for transformation by p53 produce a gene product that forms a hsc 70-p53 complex with an altered half-life. Mol Cell Biol. 8:1988;531-539.
9. Aprikian AG, Sarkis AS, Fair WR, Zhang ZF, Fuks Z, Cordon-Cardo C. Immunohistochemical determination of p53 protein nuclear accumulation in prostatic adenocarcinoma. J Urol. 151:1994;1276-1280.
10. Shurbaji MS, Kalbfleisch JH, Thurmond TS. Immunohistochemical detection of p53 protein as a prognostic indicator in prostate cancer. Hum Pathol. 26:1995;106-109.
11. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 51:1991;6304-6311.
12. Stattin P, Damber JE, Modig H, Bergh A. Pretreatment p53 immunoreactivity does not infer radioresistance in prostate cancer patients. Int J Radiat Oncol Biol Phys. 35:1996;885-889.
13. Prendergast NJ, Atkins MR, Schatte EC, Paulson DF, Walther PJ. p53 immunohistochemical and genetic alterations are associated at high incidence with post-irradiated locally persistent prostatic carcinoma. J Urol. 155:1996;1685-1691.
14. Shabaik AS, Krajewski S, Burgan A, Krajewska M, Reed JC. bcl-2 protooncogene expression in normal, hyperplastic, and neoplastic prostate tissue. J Urol Pathol. 3:1995;17-27.
15. Reed JC. bcl-2 and the regulation of programmed cell death. J Cell Biol. 124:1994;1-6.
16. Zhan Q, Fan S, Bae I, Guillouf C, Liebermann DA, O'Connor PM, Fornace AJ Jr. Induction of bax by genotoxic stress in human cells correlates with normal p53 status and apoptosis. Oncogene. 9:1994;3743-3751.
17. Furuya Y, Krajeski S, Epstein JI, Reed JC, Isaacs JT. Expression of bcl-2 and the progression of human and rodent prostatic cancers. Clin Cancer Res. 2:1996;389-398.
18. Carroll AG, Voeller HJ, Sugars L, Gelmann EP. p53 oncogene mutations in three human prostate cancer cell lines. Prostate. 23:1993;123-134.
19. Leith JT, Quaranto L, Padfield G, Michelson S, Hercbergs A. Radiobiological studies of PC-3 and DU-145 human prostate cancer cells: x-ray sensitivity in vitro and hypoxic fractions of xenografted tumors in vivo. Int J Radiat Oncol Biol Phys. 25:1993;283-287.
20. Leith JT. In vitro radiation sensitivity of the LNCaP prostatic tumor cell line. Prostate. 24:1994;119-124.
21. Berchem GJ, Bosseler M, Sugars LY, Voeller HJ, Zeitlin S, Gelmann EP. Androgens induce resistance to bcl-2 mediated apoptosis in LNCaP prostate cancer cells. Cancer Res. 55:1995;735-738.
22. Bauer JJ, Sesterhenn IA, Mostofi FK, McLeod DG, Srivastava S, Moul JW. Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer. J Urol. 156:1996;1511-1516.